# CytoCares

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytocares

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.cytocares.com
- Total disclosed funding: $14M
- Latest round: Series A (May 12, 2023)
- Investors on record: 5

## About

Based in Shanghai, China, and established in 2015, CytoCares is a biotechnology company that focused on the R&D of large molecule new drugs for tumour immunotherapy. Dr, Huaxing Zhu, the company's founder, established a listed biotechnology company, Novoprotein. In October 2025, CytoCares raised CNY 68 million in venture funding from new investor Shanghai Tellgen Life Science.
CytoCares provides cell therapy products for haematological and solid tumours. It's the first product pipeline, CC312, is a tri-specific antibody based on CD28 co-stimulatory signalling. The tri-specific antibody, CC312, is performing the clinical phase 1 studies in China and the United States, which is intended to be developed for the treatment of B-cell malignant haematological tumours. CC312, is developed based on the TriTE platform, which is a T-cell bridger-based multi-drug platform based on CD3/CD28 dual-signal T-cell activation. Compared to CD19, CC312 has the greater capacity to induce the T-cell proliferation. And CC312 can be used for preventing tumour recurrence. 
Revenue is generated through licensing of biopharmaceutical candidates, strategic partnerships, CRO services, and reagent sales. The company may also receive funding from clinical trial collaborations and government research grants.

## Funding rounds

- Series A, May 12, 2023, $14M — Jolmo Capital, Shenzhen Capital Real Estate Fund, Prosperico Ventures, Tailong VC, Xiamen Bosai Gene Transcription Technology

## Investors

- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A
- Xiamen Bosai Gene Transcription Technology — Series A